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BACKGROUND:The expression of side-population (SP) cells and their relation to tumour-initiating cells (T-ICs) have been insufficiently
studied in breast cancer (BC). We therefore evaluated primary cell cultures derived from patients and a panel of human BC cell lines
with luminal- or basal-molecular signatures for the presence of SP and BC stem cell markers.
METHODS:The SPs from luminal-type BC were analysed for BC T-IC characteristics, including human epidermal growth factor receptor
2 (HER2), ERa, IGFBP7 expression and their ability to initiate tumours in non-obese diabetic severe combined immunodeficiency
(NOD/SCID) mice. Pharmacological modulators were used to assess the effects of HER2 signalling and breast cancer-resistance
protein (BCRP) expression on SPs.
RESULTS:The SP was more prevalent in the luminal subtype of BC compared with the basal subtype. HER2 expression was significantly
correlated with the occurrence of an SP (r
2¼0.75, P¼0.0003). Disappearance of SP in the presence of Ko143, a specific inhibitor of
the ATP-binding cassette transporter BCRP, suggests that BCRP is the predominant transporter expressed in this population. The SP
also decreased in the presence of HER2 signalling inhibitors AG825 or trastuzumab, strengthening the notion that HER2 contributed
to the SP phenotype, likely through downstream AKT signalling. The SP cells from luminal-type MCF-7 cells with enforced expression
of HER2, and primary cells with luminal-like properties from a BC patient, displayed enrichment in cells capable of repopulating
tumours in NOD/SCID mice. Engraftment of SP cells was inhibited by pretreatment with AG825 or by in vivo treatment with
trastuzumab.
INTERPRETATION: Our findings indicate an important role of HER2 in regulating SP and hence T-ICs in BC, which may account for the
poor responsiveness of HER2-positive BCs to chemotherapy, as well as their aggressiveness.
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According to the stem cell hypothesis, tumour-initiating cells
(T-ICs) are the only population capable of recapitulating the original
tumour. In breast cancer (BC), a CD44
þ/CD24
–low/Lin
  cell
population was first identified as T-ICs (Al-Hajj et al, 2003).
Later, aldehyde dehydrogenase (ALDH) 1 activity was reported to
be associated with stem/progenitor properties in BC (Ginestier
et al, 2007). More recent studies showed that these T-IC
populations in BC might be regulated through human epidermal
growth factor receptor (HER) 2. In patients with HER2-positive
tumours receiving the epidermal growth factor receptor (EGFR)/
HER2 inhibitor lapatinib in an adjuvant setting, a decrease in
CD44
þ/CD24
 /low cells and tumour mammosphere-forming effi-
ciency was observed. The ALDH1
þ T-ICs were increased by
upregulation of ‘stemness’ genes through HER2 overexpression in
BC (Korkaya et al, 2008; Li et al, 2008; Magnifico et al, 2009).
However, ALDH1
þ T-ICs were more frequently detected in the
‘triple-negative’ (HER2-, oestrogen-, and progesterone receptor-
negative) basal-like-subtype BC than in luminal BC (Charafe-
Jauffret et al, 2009), suggesting that T-ICs may differ with the
subtype of BC.
Compared with CD44
þ/CD24
 low/Lin
  and ALDH1
þ T-ICs, the
effect of HER2 on side-population (SP) T-ICs has not been well
studied (Hirschmann-Jax et al, 2004; Ponti et al, 2005). The SPs
from BC contain primitive stem cell-like cells that can differentiate
into epithelial tumours in vitro and in vivo and express stemness
genes (Patrawala et al, 2005; Christgen et al, 2007). As SP cells have
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sa high drug efflux capacity owing to functional expression of ABC
transporters such as BCRP (ABCG2) and P-glycoprotein (Pgp/
ABCB1) (Hirschmann-Jax et al, 2004), T-ICs in the SP may be
more relevant to drug resistance than CD44
þ/CD24
 low/Lin
  and
ALDH1
þ T-ICs. In fact, HER2 is a predictive marker for responses
to drugs that are effluxed through BCRP and/or Pgp, including
cyclophosphamide, methotrexate and fluorouracil, (Menard et al,
2001; Wolff et al, 2007), docetaxel (Xie et al, 2008), as well as
endocrine therapies, particularly tamoxifen (Konecny et al, 2003).
Therefore, the activation of drug-resistant SP cells could provide
an explanation for the poor response of HER2-positive and
luminal-type tumours to cytotoxic chemotherapy.
A previous study of head and neck squamous cell carcinoma
indicated an increase in SP cells by activation of HER1/EGFR
signalling (Chen et al, 2006). Furthermore, the stimulatory effect of
E G Fo nB C R Pg e n et r a n s c r i p t i o nh a sb e e nr e p o r t e di nh u m a nb r e a s t
(Meyer zu Schwabedissen et al, 2006) and ovarian cancer (Nakanishi
et al, 2006b). Hence, we investigated whether HER2 could be a key
regulatory factor for T-ICs found in the SP of BC. Furthermore, we
evaluated whether HER2 can affect the engraftment of SP cells from
primary and BC cell lines in non-obese diabetic severe combined
immunodeficiency (NOD/SCID) mouse repopulation assays. In this
study, we show that the SP is prevalent and enriched for T-ICs in the
luminal-subtype BC, and that HER2 can expand T-ICs in primary
and permanent BC cells. Our data support a pivotal role for HER2 in
regulating SP cells in luminal-type BC.
MATERIALS AND METHODS
Cell culture
Human BC cell lines (MCF10A, MCF-7, T47D, MDA-MB-231,
Hs578T, MDA-MB-468, SKBR3, and BT-20) were obtained from the
American Type Culture Collection (Manassas, VA, USA). The MCF-
7 cell line transfected with human HER2, MCF-7/HER2-18, was
generated and maintained as previously described (Jerome et al,
2006). MDA-MB-231 and BT-20 cells were transfected with either
the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA) containing
human HER2 cDNA or with pcDNA3 alone. Transfectants were
selected using geneticin, and individual colonies were screened for
HER2 expression by western blots. Established HER2-overexpres-
sing MDA-MB-231 and BT-20 cells were designated as MDA-MB-
231/HER2 and BT-20/HER2, respectively. All cell lines were
cultured in RPMI 1640 medium (Mediatech Inc., Manassas, VA,
USA) containing 10% foetal bovine serum. Aromatase-transfected
MCF-7 cell lines (Ac1) and anastrozol-resistant Ac1 (Ac1ANAR)
were cultured as previously described (Zhou et al, 1990). Primary
cell cultures were established as outlined in Supplemental Methods;
they were designated as GCC-BC1 to 4, an abbreviation for
Greenebaum Cancer Center-Breast Cancer line number 1–4; their
characteristics are listed in Supplementary Table S1.
SP and fluorescence-activated cell sorting analyses
The SP protocol was essentially performed as described by Goodell
et al (1996). Cells (1 10
6 cells per ml) were incubated in
Dulbecco’s Modified Eagle’s Medium containing 5% foetal bovine
serum, 10mM HEPES, and 5mgml
–1Hoechst 33342 (H33342, from
Sigma-Aldrich, St Louis, MO, USA) for 90min at 371C with or
without BCRP inhibitor Ko143 (1mM, a gift from Dr Schellens,
Netherlands Cancer Institute). Samples were analysed by flow
cytometry (LSR I or FACSVantage SE, BD Biosciences, San Jose,
CA, USA, Supplementary Figure S1). For isolation of SP cells from
BC cell lines or from primary cultures, the FACSVantage SE cell
sorter was used. At least 10
7 cells were subjected to fluorescence-
activated cell sorting to yield sufficient SP cells for in vitro and
in vivo experiments.
Allophycocyanin-, fluorescein isothiocyanate-, or phycoerythrin-
labelled primary antibodies for phenotyping of SP cells for
surface antigens included antibodies to BCRP (R&D Systems
Inc., Minneapolis, MN, USA), HER2 (R&D Systems), Pgp, CD44, or
CD24 (from Chemicon, Gibbstown, NJ, USA). Propidium iodide
(2mgml
–1; Sigma-Aldrich) was added to discriminate dead cells.
For the determination of CD44
þ/CD24
  and ALDH1
þ cells,
2–5 10
5 cells were suspended in 50ml of 0.5% bovine serum
albumin in phosphate-buffered saline (PBS), and were then
incubated with allophycocyanin-conjugated anti-CD44, fluorescein
isothiocyanate-conjugated anti-CD24, or with both istotype con-
trols as described before (Al-Hajj et al, 2003; Hughes et al, 2008).
The ALDH1
þ cells were analysed using ALDEFLUOR (StemCell
Technologies, Vancouver, BC, Canada) according to the manu-
facturer’s instructions. Data were processed using WinMDI
software version 2.8 (http://facs.scripps.edu/software.html).
Clonogenic assay
The human tumour clonogenic assay was performed as described by
us earlier (Fiebig et al,2 0 0 4 ) .I nb r i e f ,t ot e s tin vitro tumour cell
colony-forming ability as a surrogate of self-renewal, 5000–10000
cells were seeded per well in a 24-well plate and grown until colonies
reached a diameter between 50 and 200mm. Plating efficiency was
determined as % of cells forming a colony per number of cells seeded.
Western blotting
Cells were washed with ice-cold PBS and homogenised in RIPA
buffer by sonication as previously described (Nakanishi et al,
2006c). A volume of 50mg of cell lysate was subjected to 10% SDS–
polyacrylamide gel electrophoresis. Blots were then probed with
anti-BCRP (Sigma-Aldrich), anti-HER2/c-Neu (EMD Chemicals,
Gibbstown, NJ, USA), anti-phosphorylated HER2 (Tyr 1221/1222),
anti-HER3, anti-phosphorylated HER3 (Tyr 1289), anti-AKT, anti-
phosphorylated AKT (Ser 473), anti-phospho p38 mitogen-
activated protein kinase (MAPK) (Thr180/Tyr182)(12F8) (rabbit
mAb #4631, Cell Signaling Technology Inc., Beverly, MA, USA),
and anti-b actin (Sigma). The blots were developed with horse-
radish peroxidase-conjugated secondary antibodies (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA) and Millipore chemilumi-
nescence reagent (Fisher Scientific, Pittsburgh, PA, USA). Signals
were developed with Kodak Biomax films, Buffalo, NY, USA and
signal intensities were analysed relative to b actin, using NIH
ImageJ software (Bethesda, MD, USA).
NOD/SCID mouse repopulation assay
All animal experiments were performed according to a protocol
approved by the University of Maryland Institutional Animal Care
and Use Committee (IACUC). The IACUC at the University of
Maryland follows the guidelines of UKCCCCR for the welfare of
animals and experimental neoplasia (Workman et al, 1998). A
volume of 100ml of culture medium mixed with 100ml of Matrigel
(BD Biosciences) containing 100,500 or 1000 sorted SP cells was
either transplanted immediately into the mammary gland of
6-week-old female NOD/SCID/Ncr mice (Animal Production
Facility, NCI Frederick, MD, USA) by subcutaneous injection, or
incubated with 100mM AG825 (Sigma-Aldrich) for 2h before
injection. Trastuzumab was obtained from our hospital pharmacy
and administered intraperitoneally twice weekly at a dose of
8mgkg
–1 as previously described (Jerome et al, 2006). As a
control for enrichment of T-ICs in SP cells, whole cell population
cells were injected at dilutions of 1000, 10000, and 5 10
6 into
NOD/SCID mice. Tumour growth was followed up weekly by
palpation and monitored for 6 months or until a size of
p1500mm
3 was reached (the limit defined by our IACUC
end-point criteria). The number of tumours 4100mm
3 was
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scounted over the same observation period. On termination of
experiments, animals were killed and tumours were excised and
subjected to immunohistochemistry.
Immunocytology
Sorted SP cells were fixed on glass slides by immersing thrice for
1min each in ice-cold methanol/acetone (v/v 1:1). The slides were
blocked with 5% bovine serum albumin in PBS overnight at 41C
and incubated for 2h with anti-ERa (clone 6F11, Novacastra,
Newcastle upon Tyne, UK, 1:200 in PBS), anti-IGFBP7 antibody
(1:100 in PBS, Burger et al, 1998), cytokeratin 18 (CK18), or anti-
HER2 antibodies (Cell Signaling), according to the manufacturer’s
instructions. Immunofluorescence was visualised with goat
anti-mouse fluorescein isothiocyanate- or anti-rabbit TRITC-
conjugated secondary antibodies (Sigma; 1:400, 3h), and then
counterstained with 40-6-diamidino-2-phenylindole (2mgml
–1;
Sigma-Aldrich). Immunoperoxidase staining for IGFBP7 and ERa
was performed as reported before (Burger et al, 1998). Results were
documented using a Leica DM4000 microscope with Improvision
Openlab software (Wetzlar, Germany).
Statistical analysis
Wilcoxon or Student’s t-tests were used to assess the significance
of the difference between the two means of data resulting from
in vitro assays. The Spearman’s rank coefficient test was used for
correlation analyses. The analysis of variance F-test was used to
analyse the significance of the in vivo tumour repopulation data.
The software packages used were SPSS SYSTAT version 10
(SYSTAT Software, Chicago, IL, USA) and the statistics module
of Microsoft Office Excel (version 2003).
RESULTS
T-IC type and transcriptional profiles of BC cells
Surrogate markers for breast T-ICs (CD44
þ/CD24
 , ALDH1
þ and
SP) were determined by fluorescence-activated cell sorting in a
panel of cultured BC cells with luminal (Lu) or basal (B) global
transcriptome expression profiles (Neve et al, 2006). The Lu
subtype mostly represents oestrogen receptor/ER-positive BCs that
may or may not be progesterone receptor/PR- and/or HER2-
positive tumours, whereas the B subtype lacks the expression of
these receptors, and is often designated ‘triple-negative’ (Andre
and Pusztai, 2006). Neve et al further subdivided basal-like BC cell
lines into Ba and Bb. This classification has so far not been carried
out with BC tissue; instead, the latter has been subclassified into
luminal-A, luminal-B, and luminal-C categories (Andre and
Pusztai, 2006). According to Neve et al (2006), the Ba subtype is
positive for cytokeratin 5 and 14; Bb is vimentin positive. Both Ba
and Bb exhibit a stem-like expression profile that reflects the
clinical triple-negative tumour type. The classifications of the BC
cell lines used in this study are shown in Table 1. Comparative
T-IC marker analyses are shown in Figure 1A for the MCF-7,
MDA-MB-468, and MDA-MB-231 lines, representing Lu, Ba, and
Bb subtypes, respectively. GCC-BC1–4 cells, for which gene
expression analysis has not yet been performed, were considered
to be Lu-like because of ER and CK18 expression (Supplementary
Table S1, Supplementary Figure S3). Interestingly, the prevalence
of T-IC markers among different subtypes of BC cells was different
(Figure 1A, Table 1), with SP being present in Lu-type or Lu-like
cells and low or absent in Ba/Bb-type cells.
Dot plots show the median value for the presence of breast T-IC
markers for each BC subtype (Figure 1B). Patient-derived cell lines
(Pt) were listed separately because of lack of a definitive gene
cluster analysis (Figure 1B, Table 1). The median value of the
percentage of SP cells in a given whole cell population was the
highest in Lu-subtype cells (1.09%), which was 11-fold higher than
that in Ba-subtype cells (Po0.01). The SP cells were lowest in
Bb-type cells. Whereas SP cells were mainly present in Lu-subtype
cancers (e.g., MCF-7 and GCC-BC4), ALDH1
þ cells were detected
in Lu and Ba/Bb-subtype cells such as MDA-MB-468 and MDA-
MB-231 (Figure 1A, B). The median values of ALDH1
þ cells were
almost identical in Lu-subtype (0.81%) and patient-derived cells
(0.82%). Although the Ba-subtype MDA-MB-468 cells had the
highest ALDH1
þ fraction (7.56%, Table 2, Figure 1B), the mean
percentage value of ALDH1
þ cells in the Ba subtype (0.35%) was
Table 1 SP cells and HER2 expression in human breast cancer cells
SP HER2
Cell line isogenic subclone ERa Gene cluster Rank (%) Rank MFI
MCF10A   Bb 1 0.00 (0.00, 0.00) 2 0.70±0.13
MCF-7 + Lu 7 0.39±0.15 9 40.2±11.8
MCF-7/vector + Lu — 0.29±0.21 — ND
MCF-7/TAM1 + Lu 10 0.87±0.27 10 40.9±6.30
MCF-7/HER2-18 + Lu 16 3.38±0.27 17 161.4±37.4
HC7 + Lu 18 7.31±0.55 18 170.3 (97.48, 247.16)
T47D + Lu 4 0.15±0.08 5 19.2±6.19
Ac1 + Lu 11 1.05±0.32 15 125.2±40.5
Ac1ANAR + Lu 17 6.00±0.39 14 84.9±25.8
SKBR3   Lu 12 1.41±0.27 16 156.1±83.88
BT-20   Ba   0.10±0.04   ND
BT-20/pcDNA3   Ba 5 0.17±0.08 4 7.30±1.70
BT-20/HER2   Ba 8 0.76±0.33 12 48.5±8.27
MDA-MB-468   Ba 1 0.00±0.00 1 0.00±0.00
MDA-MB-231/pcDNA3   Bb 1 0.00±0.00 3 1.50±0.84
MDA-MB231/HER2   Bb 6 0.32±0.12 13 82.6±14.5
GCC-BC1 + Lu-like 14 2.92±1.26 7 31.6±9.09
GCC-BC2 + Lu-like 15 3.15±1.97 11 45.0±8.32
GCC-BC3 + Lu-like 9 0.85±0.33 6 25.4±8.39
GCC-BC4 + Lu-like 13 2.80±0.25 8 37.6±10.8
Abbreviations: ANAR¼anastrozole resistant; TAM¼tamoxifen resistant; ND¼not done; MFI¼mean fluorescence intensity; SP¼side population; HER2¼human epidermal
growth factor receptor 2 ERa¼estrogen receptor-a. Each value represents the mean value of three independent experiments with±s.e. When an experiment was performed
only twice, each value is shown in parentheses. A rank of 1 represents the lowest value for SP and HER2 expression.
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sthe lowest among all gene clusters, because ALDH1 was not
detected in other Ba BCs, such as BT-20 cells (0.02%). A large
population of CD44
þ/CD24
  cells (80.3 and 56.7%, respectively)
was characteristic for highly metastatic Bb-subtype BC cells
(median value¼72.1%) including MDA-MB-231 or Hs578T
(Hughes et al, 2008). Importantly, all three different subtypes of
BC T-ICs were increased in MCF-7/HER2-18 cells compared with
those in parental MCF-7 cells (Table 2). In addition to a greater
than 10-fold increase in SP cells in MCF-7/HER2-18 described
above, CD44
þ/CD24
  and ALDH1
þ cells were also increased 1.53-
and 3.55-fold, respectively (Table 2). In addition, we performed
clonogenic assays as in vitro tests for self-renewal (Fiebig et al,
0.29%
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Figure 1 Association of stem cell markers with transcriptional classification of breast cancer (BC) cells. (A) The side-population (SP) cells were analysed in
MCF-7, MDA-MB-231, MDA-MB-468, and GCC-BC4 cells by Hoechst staining and flow cytometry. To determine CD44
þ/CD24
  expression, cells were
incubated with anti-CD44 (conjugated with allophycocyanin (APC)) and anti-CD24 (conjugated with fluorescein isothiocyanate (FITC)), or both isotype
controls. Aldehyde dehydrogenase 1
þ (ALDH1
þ) was analysed by measuring cellular fluorescence of bodipy-aminoacetate (BAAA) in the presence or
absence of DEAB, a specific inhibitor for ALDH1. Percentages of cell fractions positive for stem cell markers are shown in the quadrants of the graphs
containing the relevant cell population. Each plot is representative of at least three independent experiments. (B) Analysis of breast tumour-initiating cells
(T-ICs) defined as SP, CD44
þ/CD24
 , or ALDH1
þ cell fractions. Twenty-five different human BC cell lines were evaluated. Average values of each
surrogate markers for T-ICs in a given cell line were plotted in dot plots. Lu BC includes 11 cell lines: MCF-7, MCF-7/human epidermal growth factor
receptor 2 (HER2)-18, MCF-7/vector, HC-7, SKBR3, T47D, MCF-7/TAM1, MCF-7 CA, MCF-7 CA/LTLT (Sabnis et al, 2009), Ac1, and Ac1/ANAR; Ba BC
includes four lines: BT-20, BT-20/pcDNA3, BT-20/HER2, and MDA-MB468; Bb BC includes six lines: MCF10A, MDA-MB231, MDA-MB231/pcDNA3,
MDA-MB231/HER2, Hs578T, and Hs578Ti8 (Hughes et al, 2008). Because of a lack of transcriptional profiling data for the patient-derived BC lines, these
cells were classified as luminal-like and include GCC-BC1, -BC2, -BC3, and -BC4. The median percentage values are indicated by a horizontal bar. Lu,
Luminal: Ba, Basal A; Bb, Basal B; Pt, Patient-derived primary cell line. *Po0.01 vs Lu BC;
wPo0.01 vs Pt BC, by Wilcoxon test. (C) Clonogenic assay for
representative cells from panel B. The % plating efficiency (PE) representing colony-forming units in the whole cell population per 5000 seeded cells was
highest in cell lines with large SP, such as MCF-7/HER2-18, and lowest in those BC cells lacking an SP (MDA-MB-468). The data shown represent the mean
of three independent experiments.
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s2004) in a panel of cell lines from Tables 1 and 2; the percentage
plating efficiency representing colony-forming units in the whole
cell population was highest in cell lines with a large SP, such as
MCF-7/HER2-18, and lowest in those BC cells lacking an SP and
HER2, expressing low levels of CD44
þ/CD24
 , but exhibiting a
high ALDH1
þ fraction (MDA-MB-468) (Figure 1C). Overall, these
data are in support of a regulatory role of HER2 in expansion of
cells with T-IC properties.
HER2 expression and the SP in BC cells
Table 1 summarises the percentage of SP cells and surface HER2
expression in a panel of BC cells, including recently established
primary BC cell lines freshly derived from patient specimens
designated as GCC-BC1, -BC2, -BC3, and -BC4 (Supplementary
Table S1). The SP in Lu-type MCF-7/HER2-18 cells increased
substantially compared with parental and empty vector-transfected
MCF-7 cells (Figure 2A, Table 1). Another clone of MCF-7
cells transfected with HER2, designated HC7 (established by
Dr Brodie), similarly exhibited a substantial increase in SP
compared with parental MCF-7 cells (Table 1). In Ba-subtype
BC, the SP in BT-20/HER2 cells also increased compared with that
in BT-20/pcDNA3. In Bb-subtype MDA-MB-231/HER2 cells, the SP
comprised 0.32% of the total population, whereas no SP cells were
detected in MDA-MB-231/pcDNA3 (Table 1). Figure 2B depicts a
transformation of data in Table 1, shown as a Spearman’s rank
correlation of SP and HER2 expression, suggesting a strong
correlation (r¼0.75, P¼0.0003) of the rank of HER2 expression
with the rank in percentage of SP cells.
HER2 expression and expression of BCRP and Pgp in BC
cells
As BCRP is transcriptionally upregulated by HER signalling
(Meyer zu Schwabedissen et al, 2006), we investigated the effect
of HER2 on SP cells in different subtypes of BC cells using reverse
transcriptase PCR and western blot analysis. The BCRP mRNA
expression was 5.5-fold increased in MCF-7/HER2-18 cells
compared with that in parental cells (data not shown; Fisher
et al (2005); Nakanishi et al (2003)) and this translated into a
similar increase in BCRP protein expression in these isogenic cell
lines (Figure 2C). A small increase in BCRP expression was
observed in BT-20 and MDA-MB-231 cells transfected with HER2
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Table 2 Stem cell populations in breast cancer cells
SP CD44
+/CD24
  ALDH
+
Cell line Gene cluster (%) (%) (%)
MCF-7 Lu 0.39±0.15 4.80±0.49 0.33±0.19
MCF-7/HER2-18 Lu 3.38±0.27** 7.36±3.03* 1.17±0.27*
MCF-7/TAM1 Lu 0.87±0.27 20.25±0.23** 0.82±0.26*
Ac1/ANAR Lu 6.00±0.39** 0.875±0.8 0.45±0.07
MDA-MBA-468 Ba 0.00±0.00 0.29±0.17 7.56±1.26
MDA-MB-231 Bb 0.00±0.00 80.3±3.86 4.42±0.34
GCC-BC4 Lu-like 2.02±0.95 1.68±0.94 1.02±0.36
Abbreviations: SP¼side population; ALDH¼aldehyde dehydrogenase; ANAR-
anastrozole resistant. *Po0.01 and **Po0.05 vs MCF-7 by Student’s t-test. Tumour-
initiating cell markers are shown as mean values±s.e. Experiments were
independently repeated for three times.
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swhen corrected for expression of b-actin (Figure 2C). In patient-
derived human BC cells, significant expression of BCRP was
detected (Figure 2C).
As a relatively large SP was seen in Lu and Lu-like-subtype BCs,
we tested different inhibitors of ABC transporters, for example,
verapamil (50mM), FTC (10mM), and Ko143 (1mM), to
identify specific ABC transporters that function in SP cells
(Goodell et al, 1996; Allen et al, 2002). In most cell lines tested,
SP cells were completely and consistently diminished by addition
of the specific BCRP inhibitor Ko143 (Figure 2A), but not by the
Pgp inhibitor verapamil or FTC (data not shown), suggesting that
BCRP has a dominant role in defining SP cells in BC. To assess
whether the treatment of Ko143 would also affect CD44
þ/CD24
 
or ALDH
þ T-IC fractions, we analysed these markers in MCF-7/
HER2-18 cells under the same conditions used for SP experiments.
As shown in Supplementary Figure S2A, Ko143 moderately
decreased the CD44
þ/CD24
  population, but showed an increase
in the ALDH
þ fraction (data not shown), suggesting that the
BCRP inhibitor may have no specific effects on these T-IC
markers.
Relationship between hormone resistance and SP cells
To investigate the impact of hormonal therapy, particularly
hormone resistance on BC T-ICs, SP cells were analysed in
acquired tamoxifen-resistant MCF-7/TAM1 cells, aromatase-over-
expressing Ac1 cells, and the acquired aromatase inhibitor
anastrozole-resistant line, Ac1ANAR. It is noteworthy that MCF-
7/HER2-18 cells are intrinsically resistant against tamoxifen. As
shown in Figure 2D and Table 1, the percentage of SP in MCF7/
TAM1 and Ac1ANAR was increased compared with that in MCF-7
and Ac1 parental cell lines. The fraction of ALDH
þ cells increased
to a similar extent as in MCF-7/HER2-18 (Table 2, Figure 3E)
compared with parental MCF-7 cells (Figure 1A). CD44
þ/CD24
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Figure 2 Human epidermal growth factor receptor 2 (HER2) expression and side-population (SP) cells: (A) The SP was analysed in various breast cancer
(BC) cell lines. After staining with H33342, Hoechst Blue and Hoechst Green were measured using a BD LSR I. The cell population that disappeared in the
presence of 1mM of Ko143 was identified as SP cells. (B) A Spearman’s rank correlation test was performed for the BC cell lines listed in Table 1. The BC cell
lines are ranked #1 for being highest in HER2 expression or SP population and #18 for being the lowest, and then the rank for HER2 expression is plotted
to the rank for SP population. Statistical analysis shows a significant correlation between the ranks (r
2¼0.75, P¼0.0003). (C) HER2 and breast cancer-
resistance protein (BCRP) in BC cell lines were detected by western blot analysis. BCRP and HER2 were detected by immunoblotting with anti-BCRP and
anti-HER2/neu antibodies. The blot was then probed with anti-b actin as a loading control. BCRP can show two distinct bands (antibody from Sigma
#B7185) due to differences in glycosylation. (D) SP analysis in drug-resistant cells. SP was increased in hormone therapy-resistant BC cells, MCF-7/TAM and
Ac1/ANAR. (E) ALDH1 analysis in hormone-resistant BC cells. MCF-7/TAM1 and Ac1ANAR contain a ALDHþ population (top panel). Data depicted in
A–E are representative of at least three individual analyses.
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sanalysis showed different results; tamoxifen-resistant MCF/TAM1
cells had a four-fold higher CD44
þ/CD24
  expression compared
with MCF-7, whereas anastrozole-resistant cells had a five-fold
lower surface CD44
þ/CD24
  expression (Table 2).
Characterisation of SP in BC
The SP cells isolated from MCF-7/HER2-18 and GCC-BC4 cell lines
(Table 1) were subjected to immunofluorescence staining for BC
T-IC markers ERa and insulin-like growth factor binding protein 7
(IGFBP7) (Shipitsin et al, 2007). ERa was not detected in the SP of
MCF-7/HER2-18 cells, whereas it was detected in the nuclei of cells
in the whole cell population (Figure 3A). In contrast, IGFBP7 was
localised in the nuclei of SP cells but displayed only weak
cytoplasmic staining in the whole cell population (Figure 3A).
The whole cell population was used as control for SP cells
instead of isolated non-SP cells because of the cytotoxic effects of
H33342 on cells that uptake the dye (Montanaro et al, 2004).
However, clonogenic assays using a whole cell population
treated with H33342 under conditions of the SP assay
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s(5mgml
–1¼8.1mM) showed that putative T-ICs (colony-forming
units) remain viable (Supplementary Figure S2B) to 450%.
To examine the self-renewal properties of SPs, 100 and 500 SP
cells were injected into the mammary gland of NOD/SCID mice by
limited dilution technique, and tumour growth and histology were
compared with injection of 5 10
6 unsorted/bulk cells. Tumours
with sizes smaller than 100mm
3, formed from SP cells of both
MCF-7/HER2-18 (Figure 3B) and GCC-BC4 (Supplementary Figure
S2) lines, were negative for ERa and positive for nuclear IGFBP7,
consistent with the localisation of these markers in SP, as shown in
Figure 3A. Tumours of a larger size (D1500mm
3) were well
differentiated and developed stroma and blood vessels, similar to
tumours established from bulk cells or from the original patient
tumour of GCC-BC4. These tumours did express nuclear ERa and
had lost their nuclear IGFBP7 expression (Figure 3B, Supplemen-
tary Figure S3B; Sausville and Burger (2006)). The BCRP
membrane positivity was increased two- to three-fold in SP cells,
compared with non-SP cells, in both MCF-7/HER2-18 and patient-
derived GCC-BC4 cells (Supplementary Figure S1D). In contrast,
Pgp expression remained unchanged in both fractions in MCF-7/
HER2-18 (data not shown).
HER2 inhibitors can reduce the SP and prevent the
engraftment of breast T-ICs in SP cells
MCF-7/HER2-18 or GCC-BC4 cells were treated with various
concentrations of tyrphostin AG825, an experimental inhibitor of
HER2. As 50mM of AG825 abolishes phosphorylation of HER2, but
not of HER1, in human lung cancer cells (Fernandes et al, 1999),
MCF-7/HER2-18 and GCC-BC4 cells were exposed to 50mM (the
estimated IC50 value in a 5-day MTT growth assay, Supplementary
Figure S2C; Phatak et al, (2007)) and other concentrations of
AG825 for 72h. Although 100mM of AG825, the approximate IC90,
did not achieve net cell kill in a 5-day growth assay (Supplemen-
tary Figure S2C), it drastically reduced SPs in GCC-BC4. AG825
significantly reduced SP cells in a dose-dependent manner in both
cell lines that were analysed (Figure 4A and B). Statistical analysis
of the SP population in the presence of 50 (Po0.05) and 100mM
(Po0.01) of AG825 in MCF-7/HER2-18 cells revealed a significant
decrease in the percentage of SP cells to 36.9 and 18% of control,
respectively (Figure 4A). Statistically significant decreases in SP in
response to 3-day treatment with AG825 were also observed in
GCC-BC4 cultures (Figure 4B). The average of three independent
analyses of the percentage of SP in GCC-BC4 cells treated with
10mM of AG825 was 67.3% of that in control, whereas 100mM of
AG825 almost completely abolished the SP (Po0.01).
Treatment with trastuzumab (160mgml
–1, a therapeutically
achievable plasma concentration) for more than 5 days decreased
SP to 57% of that in control cells in MCF-7/HER2-18 cells and to
47% in GCC-BC4 cells (Figure 4C and D).
To verify that the decrease in SP seen with AG825 or
trastuzumab was mediated by inhibition of HER2 signalling, their
effects on phosphorylation status of HER2, HER3, and AKT (a
downstream effector of HER signalling) were studied. In MCF-7/
HER2-18 cells treated with AG825 for 72h, phosphorylated HER2
(pHER2) decreased (starting at 10mM), and was completely
abolished at 50–100mM concentrations (Figure 4E). Concomi-
tantly, pHER3 was reduced in the cells. Expression of pAKT was
markedly decreased by AG825 treatment in a concentration-
dependent manner. Similar observations were made in GCC-BC4
cells treated with AG825. The effect of AG825 on pHER3 was not
clearly detected because its overall expression was very low in
these cells. Interestingly, trastuzumab (160mgml
–1) did not reduce
pAKT in either cell line, although it did reduce HER2 and HER3
phosphorylation in MCF-7/HER2-18 cells (Figure 4E left). To
underline the importance of HER2 over HER1 signalling in relation
to a detectable SP in BC cells, we also used the selective HER1
(ErbB1, EGFR) inhibitor AG1478, which has a 100-fold higher
specificity for HER1 than HER2 (Egeblad et al, 2001). AG825, but
not AG1478, was able to downregulate HER2 in MCF-7/HER2-18
cells at their IC90 concentrations of 100mM and 10mM (Supple-
mentary Figure S2D, S4A). pHER was completely inhibited by
AG825, but only to B50% by AG1478. As a result, SP was
markedly reduced by AG825 only, and to a lesser extent by AG1478
(Supplementary Figure S4C). Moreover, in contrast to AG825,
AG1478 did not downregulate BCRP expression (Supplementary
Figure S4B vs Figure 4E), but inhibited p38 MAPK activation
(Supplementary Figure S4B), whereas AG825 did not (data not
shown).
Collectively, these observations suggest that the inhibition of
HER2 phosphorylation by AG825, resulting in cessation of the
trans phosphorylation of HER3, and thus complete blockage of
HER2 signalling through AKT, might be the predominant factor
contributing to the reduction of BC T-ICs seen in SP and tumour
repopulation assays. Treatment with up to 100mM AG825 reduced
BCRP expression by about 40% in each cell line, whereas BCRP
expression seemed to be unaltered after trastuzumab treatment
(Figure 4E).
To assess whether HER2 has a role in the self-renewal of T-ICs
in the SP in vivo, SP cells from MCF-7/HER2-18 and GCC-BC4 cells
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Figure 3 Characteristics of side-population (SP) cells. (A) Characteristics
of SP in MCF-7/human epidermal growth factor receptor 2 (HER2)-18
breast cancer (BC) cells. The expressions of ERa (fluorescein isothiocyanate
(FITC) green, left panel) and insulin-like growth factor binding protein 7
(IGFBP7) (TRITC red, middle panel) are shown by immunofluorescence
staining; whole cell population cells are compared with SP cells. The right
panel shows the merged images using 40-6-diamidino-2-phenylindole
(DAPI) counter staining (blue) to contrast the nuclei. Control cells were
probed with mouse and rabbit IgG (Santa Cruz Biotechnolog Inc.). Results
represent three independent experiments. White bars represent 15mm.
(B) The expressions of ERa and IGFBP7 were also compared in tumours
established from the whole cell population or from the SP in non-obese
diabetic severe combined immunodeficiency (NOD/SCID) mice. Shown
are expression levels of the protein in small (100mm
3) and large
(1500mm
3) size grafts arising from 500 SP cells from MCF-7/HER2-18 in
NOD/SCID mice. Results represent three independent experiments. Black
bars represent 15mm.
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swere either incubated for 2h with 100mM of AG825, or with vehicle
control, and then mixed with an equal volume of Matrigel and
immediately injected at various dilutions (100,500, or 1000 cells
per injection) into the inguinal mammary gland (#4) of NOD/SCID
mice. Trastuzumab was used as systemic treatment and injected
intraperitoneally at 8mgkg
–1 every 4 days until the experiment
was terminated. As few as 100 vehicle-treated MCF-7/HER2-18 SP
cells formed tumours in NOD/SCID mice with a total tumour
incidence of 29 out of 35 injections (Table 3), whereas the
engraftment efficiency of the whole cell population at 1000 or
10000 was 0 takes for every three injections, and at 5 10
6 was
three takes for every three injections into the mammary gland. If
SP cells were pretreated with AG825, they were unable to
repopulate tumours (0 out of 18, Po0.001). When the animals
received intraperitoneally trastuzumab, tumours repopulated from
SP cells in only 2 out of 16 cases (P¼0.02) (Table 3). When
untreated GCC-BC4 SP cells were injected, all control SP cells (8
out of 8) grew tumours. When these SP cells were pretreated with
AG825, only one out of eight injections maintained repopulating
capacity (1 out of 8, Po0.001) (Table 3). Impairment of the
engrafting capability of BC T-ICs by blocking HER2 signalling may
in part account for the remarkable efficacy of trastuzumab in
preventing recurrence in the adjuvant treatment setting in BC.
DISCUSSION
Although a regulatory role for HER2 was suggested in ALDH1
þ
T-ICs, to date, no information is available regarding HER2
expression in SP cells, a T-IC-enriched cell fraction key to therapy
resistance. Wicha and co-workers have reported that ALDH1
þ
T-ICs are more frequently detected in receptor-negative basal
subtypes of BC cell lines (16 out of 16 cells were positive for
ALDH1) than in luminal subtypes (5 out of 12 cells were positive)
(Charafe-Jauffret et al, 2009). The latter study did focus on
ALDH1
þ BC cell types only and did not include a comparison of
HER2 and ALDH1 expression with other known T-IC markers,
CD44
þ/CD24
  or SP fraction. Thus, there is a paucity of data
describing T-IC markers in different subtypes of BC.
We have examined the occurrence of SP and the effects of HER2 on
SP among receptor-negative BC cell lines (Ba and Bb subtypes) and
luminal cell lines (Lu subtype) that were also characterised for
ALDH
þ and CD44
þ/CD24
  expression. We observed that breast
T-IC markers differ by transcriptional gene expression profiles (Neve
et al, 2006), as shown in Figure 1 and Table 2; SP, CD44
þ/CD24
 ,a n d
ALDH1
þ cell fractions vary among Lu, Ba, and Bb BC cells. Whereas
SP is most frequent in Lu subtypes, Bb cells are characterised by
CD44
þ/CD24
 T-ICs, although they lack SPs. Interestingly, the
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Figure 4 Effect of inhibition of human epidermal growth factor receptor 2 (HER2)/HER3 on side-population (SP) cells. (A) Effects of HER2 inhibition by
AG825 on SP in MCF7/HER2-18 cells. MCF-7/HER2-18 cells were treated with dimethyl sulphoxide (DMSO) (vehicle), or with 50 or 100mM AG825 for
72h. Thereafter, SP cells were analysed as described. Top panels show typical SP cell analysis with % SP in the lower right corner of each panel and the bar
graph summarises the effects of HER2 inhibitor on SP in MCF-7/HER2-18 cells. Each bar represents the mean value of at least three independent
experiments with s.e.m. *Po0.05, **Po0.01 by Student’s t-test. (B) Effect of AG825 on SP cells in GCC-BC4 cells. Cells were treated with DMSO
(vehicle), or with 10 or 100mM of AG825 for 72h. The SP cells were analysed by measuring Hoechst Blue and Green fluorescence on a flow cytometer.
Experiments were repeated at least three times (% SP is indicated in the lower right corner). (C) Effects of HER2 inhibition by trastuzumab on the SP in
MCF7/HER2-18 cells. (D) Effect of trastuzumab on SP cells in GCC-BC4. K0143 was used as a specific inhibitor of SP cells expressing breast cancer-
resistance protein (BCRP) and to set the appropriate gates for the detection of the SPs. (E) Comparison of HER2, phosphorylated HER2, HER3,
phosphorylated HER3, AKT, phosphorylated AKT, and BCRP expression in MCF-7/HER2-18 and GCC-BC4 cells after treatment with the HER2 inhibitor
AG825 at different doses (as indicated) and with trastuzumab (160mgml
–1) for 72h. Experiments were repeated at least three times. Absolute intensities of
each signal were quantified using NIH Image J software, and then a relative intensity value was obtained by dividing the absolute intensity of a given protein
by that of b actin. Signal quantifications for each lane of the western blots are shown as bar graphs below.
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sassociation of SP with the Lu-subtype gene cluster was confirmed by
our primary patient cell cultures, which were all ERþ and expressed
measurable amounts of HER2 (see Supplementary Table S1), but
further studies with primary tissues must confirm the association of
C D 4 4p o s i t i v i t ya n dh i g ha c t i v i t y of ALDH1 expression with basal-
subtype cancers. If confirmed in a larger cohort of primary cancers,
the existence of distinct types of T-ICs in BC will have consequences
for targeting such cells with drugs. For example, the Lu-subtype BC
T-ICs should be more susceptible to clinically available anti-HER2
therapies such as trastuzumab or lapatinib.
We report here for the first time that HER2 expression increases
breast T-ICs in SP in a variety of human BC subtypes (Figure 2C,
Table 1). HER2/HER3 signalling may also have a role in
modulating the SP mainly through AKT (Figure 4E). Although
previous studies have reported an increase in SP cells by activation
of HER1/EGFR signalling (Chen et al, 2006), and a stimulatory
effect of EGF on BCRP gene transcription (Meyer zu
Schwabedissen et al, 2006), experiments conducted by us
comparing the effects of the HER2 inhibitor AG825 with that of
the HER1 inhibitor AG1478 (Figure 4 and Supplementary Figure
S4) demonstrate a predominant role of HER2/HER3 signalling over
HER1 signalling in regulating the SP. HER1 inhibition and, thus,
cessation of MAPK signalling could not reduce BCRP expression
in GCC-BC4 cells despite inhibition of phospho p38 MAPK
(Supplementary Figure S4B). In addition, AG1478 did not inhibit
HER2 expression and only moderately affected pHER2 expression
(Supplementary Figure S4A). This resulted in only limited effects
of AG1478 on the SP (Supplementary Figure S4C).
The importance of HER2 expression in the occurrence of a large
SP is further supported by our data resulting from the analyses of
hormone therapy-resistant BC cell lines and tumours. It has been
shown that HER2 overexpression may have a role in developing
resistance to the aromatoase inhibitor letrozole and that tumours
relapsing early while on adjuvant tamoxifen therapy exhibit high
levels of HER2 protein and/or gene amplification (Shin et al, 2006).
This may be reflected in the increased SP and HER2 expression
data for tamoxifen-resistant cell lines MCF-7/HER2-18 and MCF-7/
TAM1, and the aromatase inhibitor anastrozole-resistant cell line
Ac1ANAR (Figure 2D–E, Table 1). In fact, Brodie and colleagues
have shown that trastuzumab can reverse letrozole resistance by
restoring oestrogen receptor function and sensitivity to oestrogen
(Sabnis et al, 2009). However, in the letrozole-resistant LTLT-Ca
cell line, HER2 inhibition by trastuzumab affected pMAPK rather
than pHER2. This could explain the discrepancy seen in our
experiments with trastuzumab. The latter was unable to inhibit
pAKT, and pHER2 was affected only to a limited extent
(Figure 4E); thus, the inhibition of SP was moderate, as seen for
the MAPK inhibitor AG1478 signalling through pMAPK (Supple-
mentary Figure S4).
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Figure 4 Continued.
Table 3 NOD/SCID mouse repopulation assay
Control AG825 Trastuzumab
SP cell type SP cells injected Tumours/injections
MCF-7/HER2-18 100 11/14 0/7 0/5
500 10/13 0/9 0/8
1000 8/8 0/2 2/3
GCC-SC-4/Patient 100 4/4 1/4 —
500 4/4 0/4 —
Total 37/43
a,b 1/26
a,b 2/16
a,b
Abbreviations: NOD/SCID¼non-obese diabetic severe combined immunodefi-
ciency; SP¼side population.
aComparison within groups: control, P40.7; AG825,
Po0.001; trastuzumab, P¼0.02.
bComparison between groups: control vs AG825,
Po0.001; Control vs trastuzumab, P¼0.002. The analysis of variance F-test was used.
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regulates T-ICs in BC by activating the Wnt pathway (Korkaya
et al, 2009); however, a precise mechanism of the manner in which
Wnt signalling contributes to the BC T-IC phenotype requires
further investigation.
Analysis of the hormone-resistant cell lines for MCF-7/HER2-18,
MCF-7/TAM1, and Ac1ANAR for CD44/CD24 and ALDH expression
indicated that CD44
þ/CD24
  is doubled to quadrupled in
tamoxifen-resistant lines, but not in aromatase inhibitor-resistant
lines (Figure 2D–E, Table 2). A similar trend was seen for ALDH1;
however, the levels remained generally lower than in basal-type BCs.
A genomic profiling analysis of isolated CD44
þ (stem/
progenitor cells) and CD24
þ (mature cells) populations from
normal and invasive primary breast tissues (Shipitsin et al, 2007)
found a panel of four genes that were critical differentiation
markers, including HER2 and ER, as well as seven genes that were
associated with stem cell characteristics such as IGFBP7. The loss
of ERa expression in SP cells or in small transplanted tumours
(Figure 3, Supplementary Figure S3B) is consistent with this report
by Polyak and co-workers who found ERa downregulated in
CD44
þ compared with CD24
þ cells (Shipitsin et al, 2007).
However, in our studies, ERa was re-expressed, as the T-IC-
derived SP tumours underwent differentiation and growth
(Figure 3B, Supplementary Figure S3B). Moreover, IGFBP7,
initially identified by us as a protein that is downregulated with
disease progression in BC (Burger et al, 1998; Landberg et al,
2001), was described as a stem cell marker expressed in CD44
þ,
but not in CD24
þ cell fractions of normal and BC tissues
(Shipitsin et al, 2007). When we stained SP cells, SP-derived small
tumours, large differentiated tumours, and tumours established
from bulk cells, we found that IGFBP7 was very weakly expressed
and mainly present in the cytoplasm of differentiated/bulk tumour
cells, but was very strongly expressed in the nucleus of SP cells
(Figure 3B, Supplementary Figure S3). This is also consistent with
other stem cell literature reporting IGFBP7 as a gene that is
downregulated in differentiation pathways (Bruno et al, 2004) and
being one of the most highly expressed genes in embryonic stem
cells (Liu et al, 2006). The redistribution of IGFBP7 from the
cytoplasm into the nucleus and its upregulation indicate a possible
transcriptional function in T-ICs. Together, the IGFBP7 and ER
data and the tumour repopulation assays confirm the stem cell-like
properties of cells in the SP.
In this study, BCRP was detected by western blot in three of the
patient-derived cell lines (GCC-BC1, -BC3, and -BC4, Figure 2C)
and BCRP expression was higher in SP than in non-SP cells in
GCC-BC4 cells (Supplementary Figure S1D). As expression of
BCRP is transcriptionally regulated by HER1/HER2-mediated
signalling, the detailed mechanism of transcriptional regulation
of BCRP in T-ICs has to be clarified. Alternative promoter usage
was reported in BCRP transcription (Nakanishi et al, 2006a).
Therefore, increased expression of BCRP could be subjected to
alternative promoter usage in response to transcriptional regula-
tors specific to T-ICs in the SP. Thus, the expression of BCRP
might be an important property of SP in human BC and may
contribute to drug resistance of T-ICs in the SP. Moreover, if drug-
resistant T-ICs lead to treatment failure, their simple persistence in
a protected stem cell ‘niche’ environment throughout the course of
chemotherapy could lead to repopulation of the tumour after its
initial successful debulking, owing to chemoresponsive, mature
tumour cells. This may explain why in studies examining BCRP
expression, increased ABC transporter levels were not seen in BC
patients who received only three cycles of preoperative anthracy-
cline-based therapy compared with chemo-naı ¨ve patients (Faneyte
et al, 2002). Hence, to determine a role of BCRP and the SP in the
resistance of BC to chemotherapy, BCRP expression must be
determined in relapsed tumours.
In summary, our data provide the first evidence that SP is
enriched in T-ICs in the luminal subtype of BC, and that HER2
expression has a pivotal role in expansion of the luminal-type BC
T-IC population. As the SP in BC is identified by functional
expression of multidrug-resistant proteins, in particular BCRP, our
findings may present a new rationale for the poor response of
HER2-positive and hormone-resistant BC to conventional chemo-
therapeutics. Therefore, HER2 alone or the HER2/HER3 signalling
pathway could be effective targets to modulate or reverse drug
resistance of T-ICs in luminal subtypes of BC, resulting in
suppression of reoccurrence or metastasis of BC.
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